Evidence map›Paper›PMID 35005192›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021

Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system.

Ellen Grober, Kathryn V Papp, Dorene M Rentz, Reisa A Sperling, Keith A Johnson, Rebecca E Amariglio, Aaron Schultz, Richard B Lipton, Ali Ezzati

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Traffic-related air pollution andFrontiers in dementia · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ellen GroberDepartment of Neurology Albert Einstein College of Medicine and Montefiore Medical Center Bronx New York USA.
Kathryn V PappHarvard Aging Brain Study Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Dorene M RentzHarvard Aging Brain Study Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Reisa A SperlingHarvard Aging Brain Study Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Keith A JohnsonHarvard Aging Brain Study Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Rebecca E AmariglioHarvard Aging Brain Study Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Aaron SchultzHarvard Aging Brain Study Department of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Richard B LiptonDepartment of Neurology Albert Einstein College of Medicine and Montefiore Medical Center Bronx New York USA.
Ali EzzatiDepartment of Neurology Albert Einstein College of Medicine and Montefiore Medical Center Bronx New York USA.
Center for Pain and the Brain · USMassachusetts General Hospital · USMontefiore Medical Center · USAlbert Einstein College of Medicine · US

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI CAROL A. DERBY · 1985 to 2026
$73.9M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI Tammie Lee Smith Benzinger · 1985 to 2026
$69.5M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rebecca E Amariglio · 2010 to 2026
$50.2M
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
The A3 Study: Ante-Amyloid Prevention of Alzheimer's diseaseR01AG054029 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., JOHNSON, KEITH A. · 2016 to 2023
$20.9M
Mentoring Imaging Research in Early ADK24AG035007 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SPERLING, REISA A. · 2010 to 2020
$1.4M
Predictive analytics for cognitive decline and Alzheimer’s diseaseK23AG063993 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI EZZATI, ALI · 2020 to 2024
$984k
NIA NIH HHS K23 AG063993NIA NIH HHS K24 AG035007NIA NIH HHS P01 AG003949NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG066444NIA NIH HHS P50 AG005681NIA NIH HHS R01 AG053798NIA NIH HHS R01 AG054029NIA NIH HHS R01 AG063689NIA NIH HHS U24 AG057437
6 · The paper itself

Abstract

introductionTo assess the relationship between memory performance defined by the Stages of Objective Memory Impairment (SOMI) system and the Alzheimer's disease (AD) ATN (amyloid beta [A], pathologic tau [T], and neurodegeneration [N]) biomarker system.

methodsWe used data from the Harvard Aging Brain Study cohort to estimate the level of ATN biomarkers: amyloid beta (C-Pittsburgh compound B-positron emission tomography [PET]), tau (F-18-flortaucipir [FTP] PET), and neurodegeneration (magnetic resonance imaging volumetrics). We assessed the cross-sectional relationship of SOMI classification with global amyloid levels, entorhinal and inferior temporal tau deposition, and hippocampal atrophy.

resultsParticipants with both memory storage and retrieval deficits (SOMI-3, -4) had smaller hippocampal volumes and higher entorhinal and inferior temporal tau burden than participants with no memory impairment (SOMI-0) or mild retrieval difficulty (SOMI-1). Amyloid burden did not differ among SOMI stages. DISCUSSION: This pilot supports the close relationship between tau pathology and memory impairment across the AD continuum.  SOMI may be useful to determine eligibility for randomized controlled trials prior to the assessment of biomarker status.

Indexed as

Alzheimer's diseaseATN biomarker systemCued Selective Reminding Testmemorypreclinical Alzheimer's disease

Identifiers

PMID35005192
PMCPMC8719429
OpenAlexW4206595706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.